



(11) **EP 2 054 074 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) Int Cl.:
C07K 14/505 ^(2006.01) **A61K 38/00** ^(2006.01)

(86) International application number:
PCT/US2007/073629

(48) Corrigendum issued on:
12.11.2014 Bulletin 2014/46

(87) International publication number:
WO 2008/019214 (14.02.2008 Gazette 2008/07)

(45) Date of publication and mention
of the grant of the patent:
01.10.2014 Bulletin 2014/40

(21) Application number: **07812992.1**

(22) Date of filing: **16.07.2007**

(54) **MODIFIED ERYTHROPOIETIN**
MODIFIZIERTES ERYTHROPOIETIN
ERYTHROPOÏÉTINE MODIFIÉE

(84) Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE
SI SK TR**

(74) Representative: **Hoffmann Eitle**
Patent- und Rechtsanwälte PartmbB
Arabellastraße 30
81925 München (DE)

(30) Priority: **04.08.2006 US 835429 P**

(56) References cited:
EP-A- 1 333 036 WO-A-2004/091494
WO-A1-2004/009627 WO-A2-02/49673
WO-A2-03/029291 WO-A2-2006/089228
US-A1- 2004 266 690 US-A1- 2004 266 690
US-A1- 2005 147 661 US-A1- 2005 159 353

(43) Date of publication of application:
06.05.2009 Bulletin 2009/19

(73) Proprietor: **Prolong Pharmaceuticals, LLC**
South Plainfield, NJ 07080 (US)

(72) Inventors:
• **ABUCHOWSKI, Abraham**
Califon, NJ 07830 (US)
• **LEE, Lihysyng Stanford**
Cranbury, New Jersey 08512 (US)

• **LONG D L ET AL: "Design of homogeneous,
monopegylated erythropoietin analogs with
preserved in vitro bioactivity", EXPERIMENTAL
HEMATOLOGY, ELSEVIER INC, US, vol. 34, no.
6, 1 June 2006 (2006-06-01), pages 697-704,
XP025017483, ISSN: 0301-472X, DOI: DOI:
10.1016/J.EXPHEM.2006.02.011 [retrieved on
2006-06-01]**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).